Evidence map›Paper›PMID 41419929›Full record

ReviewMolecular cancer2025

Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.

Yanna Lei, Ning Liu, Diyuan Qin, Ming Liu, Yongsheng Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanna Lei *Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Ning Liu *Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Diyuan QinDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Ming LiuGastric Cancer Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. liuming629@wchscu.cn.
Yongsheng WangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. wangys@scu.edu.cn.

Funding

National Natural Science Foundation of China 81872489, 82073369
6 · The paper itself

Abstract

Advancements in genetic engineering and synthetic biology have markedly accelerated the development and application of chimeric antigen receptor T (CAR-T) cell therapy for cancer treatment. Despite substantial progress, the treatment of solid tumors remains challenging, with suboptimal clinical outcomes and significant unmet needs. To address these ongoing challenges, considerable efforts are being made to enhance the safety, efficacy, and overall applicability of CAR-T cells therapy. This review outlines the key tumor features that impede CAR-T efficacy, focusing on intrinsic tumor factors and the influence of the microenvironment. We then provide a comprehensive overview of the promising next-generation CAR-T designs and discuss the combinatorial approaches aimed at improving antigen recognition, functional adaptability, and antitumor response, thereby expanding the therapeutic impact of CAR-T cells in solid-tumor settings.

Indexed as

Immunotherapy, AdoptiveNeoplasmsReceptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansTreatment OutcomeTumor MicroenvironmentReceptors, Antigen, T-CellReceptors, Chimeric AntigenCAR-T cellsSolid tumorTumor heterogeneityTumor microenvironment

Identifiers

PMID41419929
PMCPMC12859922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.